INTRODUCTION
============

Atopic dermatitis is a chronic, itchy skin condition that is very common in children but may occur at any age. It is also known as eczema and atopic eczema. It is the most common form of dermatitis. Atopic dermatitis usually occurs in people who have an ;atopic tendency;. This means they may develop any or all of three closely linked conditions -atopic dermatitis, asthma and hay fever (allergic rhinitis) . Often these conditions run within families with a parent, child or sibling also affected. A family history of asthma, eczema or hay fever is particularly useful in diagnosing atopic dermatitis in infants. Atopic dermatitis affects 15\~20% of children but only 1\~2% of adults [@B015]; [@B007]; [@B026]; [@B046]. In cases of allergic disease with chronic and severe pruritus, such as atopic dermatitis, contact dermatitis and urticaria, are accompanied by severe pruritus [@B019]; [@B017]. Therefore, it is very important not only to treat the allergy but also to inhibit scratching of the lesion [@B014].

2,4-Dinitrofluorobenzene (DNFB) is used as an intermediate in the synthesis of pesticides (algicides) and some pharmaceuticals such as flurbiprofen. It is also used as a sensitizing agent and hapten in laboratory immunology and as a reagent to identify the terminal amino acids in a protein chain [@B044]; [@B031]. The repeated application of DNFB to the ears of mice results in a typical allergic dermatitis and the simultaneous production of IgE antibody against DNFB [@B024][@B025]. Repeated application of DNFB onto the mouse ear causes the ear to swell accompanied by the rise of serum specific IgE levels [@B025]. Thickening of epidermis, formation of scabs, and infiltration of abundant inflammatory cells are also induced [@B042]. Therefore DNFB-induced contact dermatitis model is a useful for evaluation of a potential treatment candidate for type I allergic dermatitis [@B021]. The effects of a drug would be based on the ear swelling and incidence of scratching behaviors in this model [@B021].

Topical steroids have been a popular choice for treating various cutaneous disorders; however, the potential for significant local and systemic adverse events, like skin atrophy and hypothalamic-pituitary-adrenal (HPA) axis suppression, has limited their use [@B012]. Among glucocorticoids, dexamethasone is the one of widely used topical steroids on atopic dermatitis [@B008]; [@B022] and has been used as a reference drug on development of the new anti-allergic agents [@B036]; [@B028].

DHU001 is a mixed herbal formula consisted of 7 types aqueous extracts - Ficis fructus, Liriopis tuber, Platycodi radix, Schisandrae fructus, Glycyrrhizae radix, Zingiberis rhizome and Menthae herba and being developed for various respiratory disorders. Among 7 types of herbal components of DHU001, Liriopis tuber [@B030], Platycodi radix [@B016], Schisandrae fructus [@B027]; [@B034], Glycyrrhizae radix [@B040], Zingiberis rhizome [@B002]; [@B010] and Menthae herba [@B037] have been used for treating various respiratory symptoms. In addition, antiinflammatory effects of Platycodi radix [@B001], Glycyrrhizae radix [@B029], Zingiberis rhizome [@B002]; [@B023] have been reported, and DHU001 itself also showed anti-inflammatory effects on the mouse xylene-induced acute inflammation [@B004]. Therefore, it also considered that oral administration of DHU001 will be ameliorated the atopic dermatitis because the allergic dermatitis induced by DNFB also showed quite similar phenomena like general inflammatory responses [@B024], [@B025]; [@B042]. When the surface of skin is inflamed, cracked or raw, many of these sting or burn when first applied. This irritation will lessen as the atopic dermatitis improves related to antiinflammation activity [@B038]; [@B035].

In the present study, the effects of DHU001 aqueous extracts were evaluated on the DNFB-induced contact dermatitis, and the results were compared with dexamethasone, 15 mg/kg intraperitoneally treated group.

MATERIALS AND METHODS
=====================

Experimental animals.
---------------------

Eighty hundred male ICR mice (6-wk old upon receipt, SLC, JAPAN) were used after acclimatization for 10 days. Animals were allocated five per polycarbonate cage in a temperature (20\~25℃) and humidity (40\~45%) controlled room. Light : dark cycle was 12 hr : 12 hr and feed (Samyang, Korea) and water were supplied free to access. About half animals are selected based on preliminary test (over 10% increases of ear thickness) and each of 5 mice per group was used for ear edema test and paw scratching test.

###### 

Herbal composition of DHU001 used in this study

  --------------------------- ----------------------------------------- -------------
  Herbs                       Scientific name                           Amounts (g)
                                                                        
  Ficis fructus               *Ficus carica* Linn.                      140
  Liriopis tuber              *Liriope spicata* Lour.                   45
  Platycodi radix             *Platycodon grandiflorum* Jacq.           60
  Schisandrae fructus         *Schisandra chinensis* Baill              22.5
  Glycyrrhizae radix          *Glycyrrhiza uralensis* Fisch             15
  Zingiberis rhizoma recens   *Zingiber officinale* Roscoe              15
  Menthae Herba               *Mentha arvensis* Linne var piperascens   20
  Total                       7 types                                   317.5
  --------------------------- ----------------------------------------- -------------

All herbs were purchase from Cho-Heung Pharmaceutical Ind. Co. (Daegu, Korea) and yield 11％ aqueous extracts were acquired.

Preparation of DHU001.
----------------------

The herbal compositions of DHU001 were listed in [Table 1](#T001){ref-type="table"}. Each herbal component was purchased from Cho-Heung Pharmaceutical Ind. Co. (Daegu, Korea) after confirmation of the morphology under microscopy. Approximated amounts of each herbal component was mixed (317.5 g) and boiled in 2 l of distilled water for 2 hours and then filtrated. The filtrate was decompressed using a rotary vacuum evaporator (Lab. Camp, Daejeon, Korea) and lyophilized in a programmable freezedryer (IlShin Lab, Daejeon, Korea) . Total acquired lyophilized extracts were 34.93 g (yield 11%) . Powders of extracts were stored in a desiccator to protect against light and moisture. It was well dissolved up to 100 mg/ml concentration levels and appeared to be a deep brown solution.

Administration of drugs.
------------------------

Two different dosages of DHU001 aqueous extracts (300 and 150 mg/kg; dissolved in distilled water) were orally administered to Dinitrophenylderivatized ovalbumin (DNP-OVA) sensitization mice once a day for 7 days, and 15 mg/kg of dexamethasone-water soluble (Sigma, MO, USA; dissolved in saline) was intraperitoneal administered as same frequencies as DHU001 extracts. In DNFB control, distilled water was orally administered instead of DHU001 extracts as same methods.

DNFB-induced contact dermatitis.
--------------------------------

DNP-OVA was prepared according to the method described by [@B006] and was used as an antigen. DNP-OVA were prepared by mixing 200 mg OVA (Sigma, MO, USA) with 100 mg 2,4-dinitrofluorobenzene (Sigma, MO, USA) for 18 h at room temperature. The number of DNP groups coupled to OVA was 3.2/molecule.

Animal selection:
-----------------

Mice were sensitized by an intraperitoneal injection of a mixture of DNP-OVA (10 μg) and aluminum hydroxide gel (1 mg) in saline (0.2 ml) . After one week, the mice were challenged by painting 10 μl of 0.1% DNFB solution in ethanol on the inside and outside of the right and left ears as previously [@B045]. About half animals showing an increment of percent change (over 15%) of ear swelling were chosen.

Sensitization:
--------------

Next day of animal selection, the mice were again sensitized by the mixture of DNP-OVA (10 mg) and aluminum hydroxide gel (1 mg) in saline (0.2 ml) .

Antigen challenge:
------------------

Challenged by painting 10 μl of 0.1% DNFB solution in ethanol on the inside of the right ears for ear swelling test, or on the hind paws of each mouse for scratching test.

Ear and Paw thickness measurements.
-----------------------------------

The thicknesses of the intact and induced ear and/or paw were measured using an electronic digital caliper (Mytutoyo, Japan) 1hr after the DNFB challenge. The % increment of thickness was expressed in percentage difference between the thickness of intact and induced sides and calculated as \[ (thicknesses of induced sides - thicknesses of intact sides) /thicknesses of intact sides\] × 100.

Ear and Paw weight measurements.
--------------------------------

1 hr after the DNFB challenge, circular sections of both sides of ear and paw were taken using a cork borer with a 7-mm diameter as previously described [@B004], and weighed using an automatic electronic balance. The % increment of weights was expressed in percentage difference between the weights of intact and induced sides and calculated as \[ (weights of induced sides - weights of intact sides) /weights of intact sides\] × 100.

Scratching behavior detection.
------------------------------

From immediately after DNFB challenges on the paw, the incidences of scratching behavior on the whole body and the site challenged with DNFB were counted for 1 hr. Behavior observation was done as previously method [@B021]. In brief, after at least 1 hr min acclimation to the experimental environment, mouse behaviors were monitored small windows served for counting the scratching. The scratching behavior was defined as movement of the hind limb excluding the movement for gait.

Histopathology.
---------------

After measuring of thickness or weights, DNFB challenged ear was sampled and fixed in 10% neutral buffered formalin after cross trimming. After paraffin embedding, 3\~4 ㎛ sections were prepared. Representative sections were stained with hematoxylin and eosin (H&E) for light microscopical examination. After that the histological profiles of individual ear were evaluated.

Histomorphometry:
-----------------

The thicknesses of anterior skin parts - from epidermis to dermis (ear cartilages were excluded) were measured using automated CCD image analyzer (DMI-300 Image Processing; DMI, Korea) under magnification 100 of microscopy (Nikkon, Japan) at body regions of ear.

Statistical analyses.
---------------------

Multiple comparison tests for different dose groups were conducted. Variance homogeneity was examined using the Levene test. If the Levene test indicated no significant deviations from variance homogeneity, the obtain data were analyzed by one way ANOVA test followed by least-significant differences multi-comparison (LSD) test to determine which pairs of group comparison were significantly different. In case of significant deviations from variance homogeneity were observed at Levene test, a nonparametric comparison test, Kruskal-Wallis H test was conducted. When a significant difference is detected in the Kruskal-Wallis H test, the Mann-Whitney U (MW) test was conducted to determine the specific pairs of group comparison, which are significantly different. Statistical analyses were conducted using SPSS for Windows (Release 6.1.3., SPSS Inc., USA) and a *P* value \< 0.05 was considered significant.

RESULTS
=======

Changes on the ear and paw thicknesses.
---------------------------------------

As results of ear and paw thickness measurements to observe the edematous changes, dramatical decreases of ear and paw thickness increments were detected in all tested groups as compared with DNFB control, respectively ([Fig. 1](#F001){ref-type="fig"} and [2](#F002){ref-type="fig"}) .

![Changes of ear thickness increments detected after 7 days of continuous oral treatment of DHU001 in DNFB-sensitized mice. Significant decreases of ear thickness increments were detected in dexamethasone and two different dosages of DHU001 aqueous extracts treated groups as compared with DNFB control, and DHU001 aqueous extracts showed clear dose-dependent inhibitions on the ear thickness increments in this study. Values are expressed mean ± S.D. of five mice; ^a^p\<0.01 as compared with DNFB control by LSD test.](toxicr-26-123-g001){#F001}

![Changes of paw thickness increments detected after 7 days of continuous oral treatment of DHU001 in DNFB-sensitized mice. Significant decreases of paw thickness increments were detected in dexamethasone and two different dosages of DHU001 aqueous extracts treated groups as compared with DNFB control, and DHU001 aqueous extracts showed clear dose-dependent inhibitions on the paw thickness increments in this study. Values are expressed mean ± S.D. of five mice; ^a^p\<0.01 as compared with DNFB control by LSD test.](toxicr-26-123-g002){#F002}

![Changes of ear weight increments detected after 7 days of continuous oral treatment of DHU001 in DNFB-sensitized mice. Significant decreases of ear weight increments were detected in dexamethasone and two different dosages of DHU001 aqueous extracts treated groups as compared with DNFB control, and DHU001 aqueous extracts showed clear dose-dependent inhibitions on the ear weight increments in this study. Values are expressed mean ± S.D. of five mice; ^a^p \< 0.01 as compared with DNFB control by LSD test.](toxicr-26-123-g003){#F003}

![Changes of paw weight increments detected after 7 days of continuous oral treatment of DHU001 in DNFB-sensitized mice. Significant decreases of paw weight increments were detected in dexamethasone and two different dosages of DHU001 aqueous extracts treated groups as compared with DNFB control, and DHU001 aqueous extracts showed clear dose-dependent inhibitions on the paw weight increments in this study. Values are expressed mean ± S.D. of five mice; ^a^p \< 0.01 as compared with DNFB control by LSD test.](toxicr-26-123-g004){#F004}

Changes on the ear and paw weights.
-----------------------------------

To detect the inducement of edematous changes, the ear and paw weights were measured on individual mice in this study. As shown in [Fig. 3](#F003){ref-type="fig"} and [4](#F004){ref-type="fig"}, significant (*P* \< 0.01) decreases of ear and paw weight increments were detected in all tested groups as compared with DNFB control, respectively.

Changes on the scratching numbers.
----------------------------------

The effects of DHU001 extracts on the pruritis were observed by measuring the frequency of scratching behaviors. In the present study, significant (*P* \< 0.01) decreases of scratching behaviors were detected in all tested groups as compared with DNFB control ([Fig. 5](#F005){ref-type="fig"}) .

Histopathological changes.
--------------------------

Marked increases of skin thickness were detected in DNFB control with severe dermis related edematous changes - loosening of connective tissues at histopathological observations, but these histopathological changes were markedly inhibited by treatment of dexamethasone, DHU001 extracts 300 and 150 mg/kg treated groups, respectively ([Fig. 6](#F006){ref-type="fig"}) . The increases of skin thickness as detected by histomorphometry were detected in DNFB control due to severe dermis edematous changes, but these edematous changes were markedly inhibited by treatment of dexamethasone and both different dosages of DHU001 extracts ([Fig. 7](#F007){ref-type="fig"}) .

![Changes of scratch responses detected after 7 days of continuous oral treatment of DHU001 in DNFB-sensitized mice. Significant decreases of scratch responses were detected in dexamethasone and two different dosages of DHU001 aqueous extracts treated groups as compared with DNFB control, and DHU001 aqueous extracts showed clear dose-dependent inhibitions on the scratch responses in this study. Values are expressed mean ± S.D. of five mice; ^a^p \< 0.01 as compared with DNFB control by LSD test.](toxicr-26-123-g005){#F005}

![Histopathological observations of the ear in the DNFB control (A) , dexamethasone (B) , DHU001 150 (C) and 300 (D) mg/kg treated groups. Note that marked increases of skin thickness (arrow) were detected in DNFB control with severe dermis edematous changes, but these increases were markedly inhibited by treatment of dexamethasone and two different dosages of DHU001 aqueous extracts treated groups as compared with DNFB control, and DHU001 aqueous extracts showed clear dose-dependent inhibitions on the ear histopathological changes induced by DNFB treatment in the present study. CA, ear hyaline cartilages; EP, epidermis; DE, dermis; All H&E stain; Scale bars = 80 ㎛.](toxicr-26-123-g006){#F006}

![Changes of anterior ear skin thicknesses detected after 7 days of continuous oral treatment of DHU001 in DNFB-sensitized mice. Significant decreases of anterior skin thicknesses were detected in dexamethasone and two different dosages of DHU001 aqueous extracts treated groups as compared with DNFB control, and DHU001 aqueous extracts showed clear dose-dependent inhibitions on the anterior skin thicknesses increments in this study. Values are expressed mean ± S.D. of five mice; ^a^p \< 0.01 as compared with DNFB control by LSD test.](toxicr-26-123-g007){#F007}

DISCUSSION
==========

Because the allergic dermatitis evoked by DNFB also showed quite similar phenomena like general inflammatory responses [@B024], [@B025]; [@B042], and DHU001 itself, also showed anti-inflammatory effects [@B004] with anti-inflammatory effects of [@B001], Glycyrrhizae radix [@B029], Zingiberis rhizome [@B002]; [@B023] among 7 types of herbal components of DHU001. Therefore, we considered that oral administration of DHU-001 will be ameliorated the atopic dermatitis. In the present study, contact dermatitis was induced by sensitization with DNP-OVA and DNFB challenge as antigen. Two different concentrations of DHU001 aqueous extracts (300 and 150 mg/kg) were orally administered to DNP-OVA sensitization mice once a day for 7 days with dexamethasone as reference. End of administration of DHU001 extracts and dexamethasone, the changes on the edematous changes and scratching (pruritis) behavior were measured.

Immediate after DNFB challenge on DNP-OVA sensitized mice ear and paw, increases of ear and paw thickness and weights were detected with increases of anterior ear skin (dermis to epidermis) thickness and paw scratching behaviors. However, these edematous and allergic changes results from DNFB treatment were dramatically inhibited by treatment of the both two different dosages of DHU001 extracts and dexamethasone in the present study.

Repeated application of DNFB onto the mouse ear causes swell accompanied by the rise of serum specific IgE levels [@B025]. Thickening of epidermis, formation of scabs, and infiltration of abundant inflammatory cells are also induced [@B042]. Therefore DNFB-induced contact dermatitis model has been used for evaluation of a potential treatment candidate for type I allergic dermatitis [@B021]. DNFB to mice sensitized by DNPOVA caused edemas similar to an occurrence of atopic dermatitis is IgE antibody dependent appearing 1 hr after application of DNFB [@B045]. In the present study, marked edematous changes, increment of thickness and weights were detected on DNFB challenged ear and paw with pruritis. However, these edematous changes induced by DNFB challenges were markedly inhibited by administration of the both dosages of DHU001. It is considered as direct evidences that DHU001 can be ameliorated the type I allergic dermatitis including atopic dermatitis and these are considered as result of anti-inflammatory effects of DHU001, itself, already reported [@B004].

The favorable effects of DHU001 on the DNFB-induced contact dermatitis detected in the present study are considered to relate with the anti-inflammatory effect of DHU001 mediated immunomodulatory effects of the herbal components already reported [@B048]; [@B041]; [@B040], because immunomodulatory agents can reduce inflammation [@B033] and, furthermore, NO synthase inhibitors can reverse several classic inflammatory symptoms [@B003]. Because oxidative stress are also involved in the pathogenesis of various types dermatitis [@B047]; [@B009] and antioxidants have been ameliorated the DNFB-induced contact dermatitis [@B039]; [@B011], the antioxidant effects of DHU001 were considered as one of key mechanisms, at least on the ameliorate effects of DHU001 on the DNFB-induced contact dermatitis detected in this study. Antioxidative effects of all 7 herbal components of DHU001; Ficis fructus [@B032], Liriopis tuber [@B013], Platycodi radix [@B043], Schisandrae fructus [@B018], Glycyrrhizae radix [@B049], Zingiberis rhizome [@B020] and Menthae herba [@B005]; were already demonstrated.

The results obtained in this study suggest that oral treatment of DHU001 also has relatively favorable effects on allergic dermatitis mediated by immunomodulatory and antioxidant effects related anti-inflammatory effects of DHU001 itself, or herbal components.
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